These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30527181)

  • 1. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Anai S; Iwama E; Yoneshima Y; Otsubo K; Tanaka K; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Dec; 126():156-161. PubMed ID: 30527181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Bandyopadhyay A; Sharma S; Behera D; Singh N
    Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
    Negoro Y; Yano R; Yoshimura M; Suehiro Y; Yamashita S; Kodawara T; Watanabe K; Tsukamoto H; Nakamura T; Kadowaki M; Morikawa M; Umeda Y; Anzai M; Ishizuka T; Goto N
    Int J Clin Oncol; 2019 Mar; 24(3):256-261. PubMed ID: 30328531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
    Sharma P; Singh N; Sharma S
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
    J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
    Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
    Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
    Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
    Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in the
    Walia HK; Singh N; Sharma S
    Future Oncol; 2021 Dec; 17(35):4925-4946. PubMed ID: 34672683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.
    Takano M; Yamamoto K; Tabata T; Minegishi Y; Yokoyama T; Hirata E; Ikeda T; Shimada M; Yamada K; Morita S; Ando Y; Hirata K; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):115-24. PubMed ID: 26862009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
    Yamasaki S; Tanimoto K; Kohno K; Kadowaki M; Takase K; Kondo S; Kubota A; Takeshita M; Okamura S
    Ann Hematol; 2015 Jan; 94(1):65-9. PubMed ID: 25055799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.